Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study

被引:17
|
作者
Yoon, Young Hee [1 ]
Kim, Ha Kyoung [2 ]
Yoon, Hee Seong [3 ]
Kang, Se Woong [4 ]
Kim, June-Gone [1 ]
Park, Kyu Hyung [5 ]
Jo, Young Joon [6 ]
Lee, Joo Yong [1 ]
Lee, Dong Hoon [1 ]
机构
[1] Univ Ulsan, Dept Ophthalmol, Asan Med Ctr, Seoul 138736, South Korea
[2] Hallym Univ, Dept Ophthalmol, Kangnam Sacred Heart Hosp, Seoul, South Korea
[3] St Marys Eye Clin, Pusan, South Korea
[4] Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Seoul, South Korea
[5] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Gyeonggi Do, South Korea
[6] Chungnam Natl Univ Hosp, Dept Ophthalmol, Taejon, South Korea
关键词
Retinal vein occlusion; Macular edema; Duration of symptom; Early treatment; Korean patients; INTRAVITREAL TRIAMCINOLONE; STANDARD-CARE; RISK-FACTORS; BRANCH; EFFICACY; SAFETY;
D O I
10.1007/s10384-014-0305-9
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
To determine the correlation between the duration of macular edema (ME) and visual outcomes among Korean patients with retinal vein occlusion (RVO). Multicenter, interventional case series. Treatment-naive patients (n = 249) with branch or central RVO (BRVO/CRVO) and ME for < 6 months were included. We assessed the correlation between the duration of ME and treatment outcomes including the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) improvement, the proportion of patients achieving at least a 3-line gain in BCVA, and the mean reduction in central retinal thickness (CRT) at 6 months. One hundred and fifty-six patients with BRVO and 93 patients with CRVO were divided into five groups based on the duration of ME (< 2, 2-4 weeks, 1-2, 2-3, 3-6 months); the mean baseline BCVA and CRT among the groups did not differ significantly. In BRVO, the mean logarithm of the minimum angle of resolution (logMAR) BCVA improvements in the groups were 0.51, 0.32, 0.17, 0.19, and 0.13, respectively (P = 0.002). The respective percentages of at least 3-line gains were 64, 53, 39, 38, and 21 % (P < 0.001). The BCVA didn't significantly improve in CRVO. The decrease in CRT was not correlated significantly with the duration of ME in either disease. Treatment of BRVO as early as 2 weeks after onset of ME enhanced the visual outcome; there was no correlation in the patients with CRVO. This finding supports the current trend favoring early treatment to obtain better visual outcomes in patients with BRVO.
引用
收藏
页码:146 / 154
页数:9
相关论文
共 50 条
  • [21] Long-Term Outcomes of Anti-VEGF Treatment in Patients with Macular Edema Secondary to Retinal Vein Occlusions
    Wai, Karen M.
    Young, Jason
    Silva, Fabiana Queiroga de Paula Araujo
    Srivastava, Sunil K.
    Ehlers, Justis
    Rachitskaya, Aleksandra V.
    Kaiser, Peter K.
    Schachat, Andrew
    Babiuch, Amy Shrader
    Yuan, Alex
    Singh, Rishi P.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [22] Effects of Macular Ischemia and Early Treatment on Visual Outcome in Branch Retinal Vein Occlusion
    Han, Jung Bin
    Seo, Kyung Hoon
    Yu, Seung-Young
    Kwak, Hyung-Woo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [23] Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study
    Ogura, Yuichiro
    Roider, Johann
    Korobelnik, Jean-Francois
    Holz, Frank G.
    Simader, Christian
    Schmidt-Erfurth, Ursula
    Vitti, Robert
    Berliner, Alyson J.
    Niemeyer, Florian
    Stemper, Brigitte
    Zeitz, Oliver
    Sandbrink, Rupert
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 158 (05) : 1032 - 1038
  • [24] Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study
    Calugaru, Dan
    Calugaru, Mihai
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (03) : 607 - 608
  • [25] Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide
    Yepremyan, M
    Wertz, FD
    Tivnan, T
    Eversman, L
    Marx, JL
    OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (01) : 30 - 36
  • [26] Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept
    Qi Zhang
    Yinfen Hou
    Xiao Cao
    Rongrong Zhang
    Yinping Liu
    Chenghua Wei
    Changfan Wu
    Lixin Mei
    Pengfei Zhang
    BMC Ophthalmology, 21
  • [27] Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept
    Zhang, Qi
    Hou, Yinfen
    Cao, Xiao
    Zhang, Rongrong
    Liu, Yinping
    Wei, Chenghua
    Wu, Changfan
    Mei, Lixin
    Zhang, Pengfei
    BMC OPHTHALMOLOGY, 2021, 21 (01)
  • [28] Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion
    Ivana Gardašević Topčić
    Maja Šuštar
    Jelka Brecelj
    Marko Hawlina
    Polona Jaki Mekjavić
    Documenta Ophthalmologica, 2014, 129 : 27 - 38
  • [29] Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion
    Kleanthis Manousaridis
    Silvia Peter
    Stefan Mennel
    International Ophthalmology, 2017, 37 : 47 - 53
  • [30] Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion
    Manousaridis, Kleanthis
    Peter, Silvia
    Mennel, Stefan
    INTERNATIONAL OPHTHALMOLOGY, 2017, 37 (01) : 47 - 53